Bavarian Nordic — December 2020
-
Danke Bank: "We believe the 9% share price decrease on the dasiglucagon CHI Phase 3 trial failure is an overreaction as (1) niche indication worth only DKK13 per share, (2) no negative spill over as we see dasiglucagon as well validated with established proof-of-concept and (3) trial-design failure rather than a drug-related failure. We keep our Buy but adjust our 12-month target price from DKK310 to DKK305."
-
Som I går virker køberne til at komme ind i Z
P på 208-212 - -
GS sænker target fra 285 til 253 i ZP
-
Fortsat Buy
-
smukt - den nævnte bund holdt 222
.4 op3 % -
-
BAVARIAN NORDIC SECURES SECOND PART OF SMALLPOX VACCINE ORDER FROM THE U.S. GOVERNMENT https://www.bavarian-nordic.com/investor/news/news.aspx?news=6144
-
Bavarian Nordic sikrer sig anden del af koppevaccineordre fra USA-GENThttps://www.proinvestor.com/investornyt/670452/bavarian-nordic-sikrer-sig-anden-del-af-koppevaccineordre-fra-usa-gent
-
Bava er sgu en sjov aktie. Så tror man at den endelig kommer over 200 igen, og så ligger den bare og siver
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind